What kind of patients with castration-na ïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis

The field of systemic therapies for late-stage prostate cancer has remarkably progressed in the past 10 years; however, patients with metastatic castration-na ïve prostate cancer (mCNPC, M1) had limited improvement in overall survival (OS) [1,2]. In this context, some experts argue that optimal sequential or early combination therapy with novel agents showing clear survival benefit in metastatic castration-resistant prostate cancer (mCRPC) have the poten tial to delay disease progression and bring greater opportunity to improve survival in patients with de novo mCNPC.

Source: Urologic Oncology: Seminars and Original Investigations - October 10, 2018 Category: Urology & Nephrology Authors: Guangxi Sun, Xingming Zhang, Junru Chen, Banghua Liao, Zhenhua Liu, Jinge Zhao, Allen C. Gao, Yaojing Yang, Kunpeng Shu, Jiandong Liu, Peng Zhao, Pengfei Shen, Hao Zeng Source Type: research